SAB Biotherapeutics, Inc. Overview
Pro stress-test →SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases, with SAB-142 as its lead product candidate—a disease-modifying immunotherapy in Phase 2b clinical trials for type 1 diabetes. The company uses its proprietary DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without requiring human donors.
Strategic Profile
Pro stress-test →SAB's proprietary DiversitAb platform enables rapid and efficient production of targeted human polyclonal antibodies without reliance on human plasma, a key differentiating factor. The registrational Phase 2b SAFEGUARD study for SAB-142 is on track to complete enrollment by end-2026 with topline data expected in 2H 2027, positioning the company for potential market entry in the large type 1 diabetes therapeutic space.
Competitive Landscape
Pro stress-test →SAB's platform targets infectious diseases (COVID-19, influenza), immune and autoimmune disorders (type 1 diabetes), organ transplantation, and cancer. Primary competition in T1D immunotherapy comes from established immunosuppressants and emerging monoclonal antibody therapies. SAB's differentiation lies in its fully-human polyclonal antibody approach versus traditional small molecules and single-epitope monoclonal antibodies.
Industry Context
SAB Biotherapeutics, Inc. operates in Biopharmaceutical - Clinical-stage immunotherapy development.
Key facts
Founded: 2014 · Headquarters: Miami Beach, Florida · Employees: Not publicly disclosed · Revenue: Pre-commercial · Market cap: $177.3M